Multifocal intraocular lens exchange by a different multifocal technology: causes, visual outcomes, and patient satisfaction

Session Details

Session Title: Moderated Poster Session: EDOF vs Multifocal IOLs

Venue: Poster Village: Pod 1

First Author: : J.Alio SPAIN

Co Author(s): :    O. Al-Shymali                       

Abstract Details

Purpose:

To report causes and visual outcomes in a series of cases in which multifocal IOLs were exchanged by another multifocal technology

Setting:

Vissum, Ophthalmology Institute of Alicante, Alicante, Spain. Division of Ophthalmology, Miguel Hernández University, Alicante, Spain

Methods:

27 eyes of 17 patients, 9 female and 8 male, were included in the study and had a multifocal IOL explantation followed by another multifocal IOL technology implantation. Diffractive substituted by refractive varifocal and conversely. Outcome measures included, best corrected visual acuity (BCVA), types of IOLs, causes of exchange and patients satisfaction measured by a specific questionnaire.

Results:

The explanted IOLs included refractive (51.9%), diffractive (33.3%) and extended depth of focus (14.8%), and the implanted were 44.4% refractive IOLs and 55.6% diffractive ones. The mean duration primary surgery-explantation was 0.95 years (SD=2.05). Exchange reasons included: neuroadaptation failure (40.7%), IOL dislocation (7.4%), unsatisfactory both near and far vision (37%), unsatisfactory near vision (7.4%) and blurred vision with negative dysphotopsia (7.4%). The mean BCVA changed significantly from 20/30 to 20/22 post-exchange (p=0). The mean follow-up time is 6 months. Most patients were satisfied. Intraoperatively, zonular dehiscence was encountered in 2 eyes with no case of postoperative complications.

Conclusions:

Multifocal IOL exchange by another multifocal IOL technology may be considered a safe procedure. In patients with unsatisfactory vision or neuroadaptation failure, IOL exchange using a different optical multifocal technology can successfully treat the cases of neuroadaptation failure and provide good visual outcomes.

Financial Disclosure:

None